Endogena

Endogena Therapeutics is focused on developing innovative treatments for rare and degenerative diseases related to aging and genetic disorders. Their unique approach involves harnessing the body's own regenerative potential through the use of endogenous medicines to repair and regenerate tissues and organs. Endogena is developing treatments for retinal diseases such as retinitis pigmentosa and age-related macular degeneration and exploring therapies for conditions like idiopathic pulmonary fibrosis. Endogena has a lead product, EA-2353, which is a promising drug candidate for retinitis pigmentosa, currently in Phase 1/2a clinical trials. Endogena's innovative approach has the potential to revolutionize the treatment of rare and degenerative diseases by leveraging the body's natural healing mechanisms.

Jobs: